For Rare Innovation, One Size Does Not Fit All
Washington, D.C. (09-29-2021) – The Rare Access Action Project, (RAAP), released an updated
study reflecting the impact to companies that develop treatments for Rare Diseases through
proposed Congressional plans to change Medicare Part D. Rare Diseases are defined as
conditions that impact fewer than 200,000 people and that often have no treatments of any
kind.
